<--- Back to Details
First PageDocument Content
Graft-versus-host disease / B-cell chronic lymphocytic leukemia / Donor lymphocyte infusion / Organ transplantation / Fludarabine / Allotransplantation / Peripheral stem cell transplantation / Myelodysplastic syndrome / Multiple myeloma / Medicine / Transplantation medicine / Hematopoietic stem cell transplantation
Date: 2012-06-16 02:41:38
Graft-versus-host disease
B-cell chronic lymphocytic leukemia
Donor lymphocyte infusion
Organ transplantation
Fludarabine
Allotransplantation
Peripheral stem cell transplantation
Myelodysplastic syndrome
Multiple myeloma
Medicine
Transplantation medicine
Hematopoietic stem cell transplantation

Microsoft Word - NMA32010.doc

Add to Reading List

Source URL: www.oregon.gov

Download Document from Source Website

File Size: 282,00 KB

Share Document on Facebook

Similar Documents

Lifebank_Logo_withTag-centered

Lifebank_Logo_withTag-centered

DocID: 1rakV - View Document

NIH Public Access Author Manuscript Clin Lymphoma Myeloma. Author manuscript; available in PMC 2009 November 30. NIH-PA Author Manuscript

NIH Public Access Author Manuscript Clin Lymphoma Myeloma. Author manuscript; available in PMC 2009 November 30. NIH-PA Author Manuscript

DocID: 1qxR7 - View Document

Microsoft Word - blood_cancer_gene_sanger_institute_release

Microsoft Word - blood_cancer_gene_sanger_institute_release

DocID: 1qeRh - View Document

Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016

Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016

DocID: 1pn6V - View Document

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES www.mjhid.org ISSNOriginal Article Clinical Analysis and Optimization of Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Resid

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES www.mjhid.org ISSNOriginal Article Clinical Analysis and Optimization of Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Resid

DocID: 1oCtU - View Document